Cargando…
Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature
OBJECTIVE: Serous tubal intraepithelial carcinoma (STIC) is a precursor lesion of pelvic high-grade serous carcinoma (HGSC). Information on treatment and outcome of isolated STIC is rare. Therefore, we reviewed systematically the published literature to determine the incidence of subsequent HGSC in...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472545/ https://www.ncbi.nlm.nih.gov/pubmed/36119503 http://dx.doi.org/10.3389/fonc.2022.951292 |
_version_ | 1784789325139935232 |
---|---|
author | Linz, Valerie Catherine Löwe, Amelie van der Ven, Josche Hasenburg, Annette Battista, Marco Johannes |
author_facet | Linz, Valerie Catherine Löwe, Amelie van der Ven, Josche Hasenburg, Annette Battista, Marco Johannes |
author_sort | Linz, Valerie Catherine |
collection | PubMed |
description | OBJECTIVE: Serous tubal intraepithelial carcinoma (STIC) is a precursor lesion of pelvic high-grade serous carcinoma (HGSC). Information on treatment and outcome of isolated STIC is rare. Therefore, we reviewed systematically the published literature to determine the incidence of subsequent HGSC in the high- and low-risk population and to summarize the current diagnostic and therapeutic options. METHODS: A systematic review of the literature was conducted in MEDLINE-Ovid, Cochrane Library and Web of Science of articles published from February 2006 to July 2021. Patients with an isolated STIC diagnosis and clinical follow-up were included. Study exclusion criteria for review were the presence of synchronous gynaecological cancer and/or concurrent non-gynaecological malignancies. RESULTS: 3031 abstracts were screened. 112 isolated STIC patients out of 21 publications were included in our analysis with a pooled median follow-up of 36 (interquartile range (IQR): 25.3-84) months. 71.4% of the patients had peritoneal washings (negative: 62.5%, positive: 8%, atypic cells: 0.9%). Surgical staging was performed in 28.6% of all STICs and did not show any malignancies. 14 out of 112 (12.5%) patients received adjuvant chemotherapy with Carboplatin and Paclitaxel. Eight (7.1%) patients developed a recurrence 42.5 (IQR: 33-72) months after isolated STIC diagnosis. Cumulative incidence of HGSC after five (ten) years was 10.5% (21.6%). Recurrence occurred only in BRCA1 carriers (seven out of eight patients, one patient with unknown BRCA status). CONCLUSION: The rate of HGSC after an isolated STIC diagnosis was 7.1% with a cumulative incidence of 10.5% (21.6%) after five (ten) years. HGSC was only observed in BRCA1 carriers. The role of adjuvant therapy and routine surveillance remains unclear, however, intense surveillance up to ten years is necessary. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42021278340. |
format | Online Article Text |
id | pubmed-9472545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94725452022-09-15 Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature Linz, Valerie Catherine Löwe, Amelie van der Ven, Josche Hasenburg, Annette Battista, Marco Johannes Front Oncol Oncology OBJECTIVE: Serous tubal intraepithelial carcinoma (STIC) is a precursor lesion of pelvic high-grade serous carcinoma (HGSC). Information on treatment and outcome of isolated STIC is rare. Therefore, we reviewed systematically the published literature to determine the incidence of subsequent HGSC in the high- and low-risk population and to summarize the current diagnostic and therapeutic options. METHODS: A systematic review of the literature was conducted in MEDLINE-Ovid, Cochrane Library and Web of Science of articles published from February 2006 to July 2021. Patients with an isolated STIC diagnosis and clinical follow-up were included. Study exclusion criteria for review were the presence of synchronous gynaecological cancer and/or concurrent non-gynaecological malignancies. RESULTS: 3031 abstracts were screened. 112 isolated STIC patients out of 21 publications were included in our analysis with a pooled median follow-up of 36 (interquartile range (IQR): 25.3-84) months. 71.4% of the patients had peritoneal washings (negative: 62.5%, positive: 8%, atypic cells: 0.9%). Surgical staging was performed in 28.6% of all STICs and did not show any malignancies. 14 out of 112 (12.5%) patients received adjuvant chemotherapy with Carboplatin and Paclitaxel. Eight (7.1%) patients developed a recurrence 42.5 (IQR: 33-72) months after isolated STIC diagnosis. Cumulative incidence of HGSC after five (ten) years was 10.5% (21.6%). Recurrence occurred only in BRCA1 carriers (seven out of eight patients, one patient with unknown BRCA status). CONCLUSION: The rate of HGSC after an isolated STIC diagnosis was 7.1% with a cumulative incidence of 10.5% (21.6%) after five (ten) years. HGSC was only observed in BRCA1 carriers. The role of adjuvant therapy and routine surveillance remains unclear, however, intense surveillance up to ten years is necessary. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42021278340. Frontiers Media S.A. 2022-08-31 /pmc/articles/PMC9472545/ /pubmed/36119503 http://dx.doi.org/10.3389/fonc.2022.951292 Text en Copyright © 2022 Linz, Löwe, van der Ven, Hasenburg and Battista https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Linz, Valerie Catherine Löwe, Amelie van der Ven, Josche Hasenburg, Annette Battista, Marco Johannes Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature |
title | Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature |
title_full | Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature |
title_fullStr | Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature |
title_full_unstemmed | Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature |
title_short | Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature |
title_sort | incidence of pelvic high-grade serous carcinoma after isolated stic diagnosis: a systematic review of the literature |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472545/ https://www.ncbi.nlm.nih.gov/pubmed/36119503 http://dx.doi.org/10.3389/fonc.2022.951292 |
work_keys_str_mv | AT linzvaleriecatherine incidenceofpelvichighgradeserouscarcinomaafterisolatedsticdiagnosisasystematicreviewoftheliterature AT loweamelie incidenceofpelvichighgradeserouscarcinomaafterisolatedsticdiagnosisasystematicreviewoftheliterature AT vandervenjosche incidenceofpelvichighgradeserouscarcinomaafterisolatedsticdiagnosisasystematicreviewoftheliterature AT hasenburgannette incidenceofpelvichighgradeserouscarcinomaafterisolatedsticdiagnosisasystematicreviewoftheliterature AT battistamarcojohannes incidenceofpelvichighgradeserouscarcinomaafterisolatedsticdiagnosisasystematicreviewoftheliterature |